Protagonist Therapeutics, Inc Contracts & Agreements

Third Amendment to Lease dated March 6, 2017 by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord, dated May 6, 2024 (Filed With SEC on August 6, 2024)

License and Collaboration Agreement by and between Protagonist Therapeutics, Inc. and Takeda Pharmaceuticals USA, Inc. dated January 31, 2024 (Filed With SEC on May 7, 2024)

Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on February 27, 2024)

Form of Pre-Funded Warrant (Filed With SEC on November 2, 2023)

Underwriting Agreement, dated April 4, 2023 (Filed With SEC on April 10, 2023)

Severance Agreement, by and between Protagonist Therapeutics Inc. and Arturo Molina, M.D., Ph.D., dated November 7, 2022 (Filed With SEC on March 15, 2023)

Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on March 15, 2023)

Offer Letter, by and between Protagonist Therapeutics Inc. and Arturo Molina, M.D., Ph.D., dated November 1, 2022 (Filed With SEC on March 15, 2023)

Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on February 28, 2022)

Second Amendment to the Exclusive Janssen License and Collaboration Agreement, dated July 27, 2021, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc (Filed With SEC on November 3, 2021)

Arbitration Resolution Agreement, dated August 4th, 2021, by and among Protagonist Therapeutics, Inc. and Zealand Pharma, A/S (Filed With SEC on November 3, 2021)

Second Amendment to Lease, dated August 10, 2021, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord (Filed With SEC on November 3, 2021)

Underwriting Agreement, dated June 15, 2021 (Filed With SEC on June 17, 2021)

Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on March 10, 2021)

Underwriting Agreement, dated December 10, 2020 (Filed With SEC on December 11, 2020)

Severance Agreement, dated August 4, 2020, by and between Protagonist Therapeutics, Inc. and Don Kalkofen (Filed With SEC on August 6, 2020)

Underwriting Agreement, dated as of May 11, 2020 (Filed With SEC on May 12, 2020)

Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on March 10, 2020)

Protagonist Therapeutics, Inc. Amended and Restated 2018 Inducement Plan (Filed With SEC on February 24, 2020)

Open Market Sale AgreementSM, dated November 27, 2019, by and between Protagonist Therapeutics, Inc. and Jefferies LLC (Filed With SEC on November 27, 2019)

Severance Agreement, dated July 19, 2019, by and between Protagonist Therapeutics, Inc. and Samuel Saks, M.D (Filed With SEC on November 6, 2019)

First Amendment to Exclusive License and Collaboration Agreement, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., dated May 7, 2019 (Filed With SEC on August 7, 2019)

Offer Letter between Protagonist Therapeutics, Inc. and Donald Kalkofen, dated May 20, 2019 (Filed With SEC on May 29, 2019)

Separation Agreement between Protagonist Therapeutics, Inc. and Richard S. Shames, dated May 7, 2019 (Filed With SEC on May 13, 2019)

Severance Agreement, dated March 14, 2019, by and among Protagonist Therapeutics, Inc. and Suneel Gupta, Ph.D (Filed With SEC on May 8, 2019)

First Amendment, dated January 31, 2019, to Lease, dated March 6, 2017, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center LP (Filed With SEC on May 8, 2019)

Form of Warrant (Filed With SEC on December 31, 2018)

Exchange Agreement between Protagonist Therapeutics, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P.,... (Filed With SEC on December 31, 2018)

Form of Registration Rights Agreement (Filed With SEC on August 7, 2018)

Employment Offer Letter by and between the Company and Samuel Saks, M.D. dated as of May 21, 2018 (Filed With SEC on August 7, 2018)

Form of Class A Common Stock Purchase Warrant (Filed With SEC on August 7, 2018)

Form of Class B Common Stock Purchase Warrant (Filed With SEC on August 7, 2018)

Underwriting Agreement, dated as of October 11, 2017, by and among Protagonist Therapeutics, Inc., Leerink Partners LLC and Barclays Capital Inc (Filed With SEC on October 13, 2017)

LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN JANSSEN BIOTECH, INC. AND PROTAGONIST THERAPEUTICS, INC. (Filed With SEC on July 31, 2017)

LEASE by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware limited partnership and PROTAGONIST THERAPEUTICS,INC., a Delaware corporation Table of Contents (Filed With SEC on March 7, 2017)

FOURTH AMENDMENT TO LEASE (Filed With SEC on September 15, 2016)

ABANDONMENTAGREEMENT (Filed With SEC on August 9, 2016)

DATED 16 JUNE 2012 (1) ZEALAND PHARMA A/S (2) PROTAGONIST PTY. LTD. (3) PROTAGONIST THERAPEUTICS, INC. RESEARCHCOLLABORATION AND LICENSE AGREEMENT ZEALAND PHARMA/PROTAGONIST... (Filed With SEC on August 9, 2016)

CONTRACTEXTENSION LETTER OF AGREEMENT hereinafter (Contract Extension) made effective as of June 1st 2013 (Contract Extension Effective Date). (Filed With SEC on August 9, 2016)

Agreement onaddition of Additional Collaboration Program hereinafter (AACP) made effective as of September 16th 2013 (AACP Effective Date). (Filed With SEC on August 9, 2016)

AGREEMENT TOASSIGN PATENT APPLICATIONS (Filed With SEC on August 9, 2016)

PROTAGONIST THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JULY 28, 2016 APPROVED BY THE STOCKHOLDERS:JULY 31, 2016 EFFECTIVE DATE: JULY 28, 2016 (Filed With SEC on August 1, 2016)

PROTAGONIST THERAPEUTICS, INC. (a Delaware corporation) [] Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on August 1, 2016)

Additional abbreviations may also be used though not in the above list. (Filed With SEC on August 1, 2016)

PROTAGONIST THERAPEUTICS, INC. THIRD AMENDEDAND RESTATED INVESTOR RIGHTS AGREEMENT July 31, 2016 PROTAGONIST THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS... (Filed With SEC on August 1, 2016)

PROTAGONIST THERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JULY 28, 2016 APPROVED BY THE STOCKHOLDERS:JULY 31, 2016 (Filed With SEC on August 1, 2016)

INDEMNITY AGREEMENT (Filed With SEC on August 1, 2016)

EMPLOYEE SEVERANCE AGREEMENT (Filed With SEC on August 1, 2016)

Agreement onaddition of Additional Collaboration Program hereinafter (AACP) made effective as of September 16th 2013 (AACP Effective Date). (Filed With SEC on July 11, 2016)

ABANDONMENTAGREEMENT (Filed With SEC on July 11, 2016)

AGREEMENT TOASSIGN PATENT APPLICATIONS (Filed With SEC on July 11, 2016)

CONTRACTEXTENSION LETTER OF AGREEMENT hereinafter (Contract Extension) made effective as of June 1st 2013 (Contract Extension Effective Date). (Filed With SEC on July 11, 2016)

DATED 16 JUNE 2012 (1) ZEALAND PHARMA A/S (2) PROTAGONIST PTY. LTD. (3) PROTAGONIST THERAPEUTICS, INC. RESEARCHCOLLABORATION AND LICENSE AGREEMENT (Filed With SEC on July 11, 2016)

THIRD AMENDMENT TO LEASE (Filed With SEC on July 11, 2016)

SECOND AMENDMENT TO LEASE (Filed With SEC on July 11, 2016)

FIRST AMENDMENT TO LEASE (Filed With SEC on July 11, 2016)

LEASE (Filed With SEC on July 11, 2016)

PROTAGONIST THERAPEUTICS, INC. 2007 STOCK OPTION AND INCENTIVE PLAN (AS AMENDED AND RESTATED) (Filed With SEC on July 11, 2016)

PROTAGONIST THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORRIGHTS AGREEMENT July 10, 2015 PROTAGONIST THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS... (Filed With SEC on July 11, 2016)

Category

Industry

Companies

Contracts

Protagonist Therapeutics, Inc Contracts & Agreements